Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
Retrieved on:
Thursday, September 28, 2023
Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. (" Triastek ") today announced the completion of a USD 20.4 million Pre-C financing round.
Key Points:
- Nanjing, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Triastek, Inc. (" Triastek ") today announced the completion of a USD 20.4 million Pre-C financing round.
- Triastek’s proprietary technology, the Melt Extrusion Deposition (MED®) 3D printing process, combined with digital formulation development methods, enables complex drug delivery and programmed release.
- Triastek, as a leading provider of digital pharmaceutical process technology, is continuously advancing applications of 3D printing technology to produce novel pharmaceutical products that improve patient outcomes.
- The company has engaged in extensive business collaborations with global pharmaceutical companies, focusing on novel products and advanced technical solutions.